Abstract
Despite important advances made in the last century, infectious diseases caused by pathogenic microrganisms are still a major threat to human health. This is worsened by the occurrence of new forms of bacterial resistance against antibiotics, that are the main remedy against infectious diseases, and their rapid spreading across bacterial species, pose additional threats to our health. Thus, the necessity to develop new weapons against pathogenic bacteria is widely recognized as a major challenge for modern drug research. Traditional antibiotic discovery procedures have so far focused on inhibiting the main processes of the bacterial cell (replication, transcription, translation, and peptidoglycan synthesis). This review will give an overview of the therapeutic strategies to cure infectious diseases caused by Gram-negative bacteria through the development of inhibitors of Kdo biosynthesis. Kdo is a monsaccharide essential for OM biogenesis, OM being an essential cellular structure shared by all Gram-negative bacteria. Hence, inhibitors of its biosynthesis can have a broad-spectrum antibacterial activity.
Keywords: LPS, enzyme inhibitors, Kdo, Lipid A, Gram-negative bacteria, antibiotics, enzyme structure
Current Drug Discovery Technologies
Title: The Kdo Biosynthetic Pathway Toward OM Biogenesis as Target in Antibacterial Drug Design and Development
Volume: 6 Issue: 1
Author(s): Laura Cipolla, Alessandra Polissi, Cristina Airoldi, Paolo Galliani, Paola Sperandeo and Francesco Nicotra
Affiliation:
Keywords: LPS, enzyme inhibitors, Kdo, Lipid A, Gram-negative bacteria, antibiotics, enzyme structure
Abstract: Despite important advances made in the last century, infectious diseases caused by pathogenic microrganisms are still a major threat to human health. This is worsened by the occurrence of new forms of bacterial resistance against antibiotics, that are the main remedy against infectious diseases, and their rapid spreading across bacterial species, pose additional threats to our health. Thus, the necessity to develop new weapons against pathogenic bacteria is widely recognized as a major challenge for modern drug research. Traditional antibiotic discovery procedures have so far focused on inhibiting the main processes of the bacterial cell (replication, transcription, translation, and peptidoglycan synthesis). This review will give an overview of the therapeutic strategies to cure infectious diseases caused by Gram-negative bacteria through the development of inhibitors of Kdo biosynthesis. Kdo is a monsaccharide essential for OM biogenesis, OM being an essential cellular structure shared by all Gram-negative bacteria. Hence, inhibitors of its biosynthesis can have a broad-spectrum antibacterial activity.
Export Options
About this article
Cite this article as:
Cipolla Laura, Polissi Alessandra, Airoldi Cristina, Galliani Paolo, Sperandeo Paola and Nicotra Francesco, The Kdo Biosynthetic Pathway Toward OM Biogenesis as Target in Antibacterial Drug Design and Development, Current Drug Discovery Technologies 2009; 6 (1) . https://dx.doi.org/10.2174/157016309787581093
DOI https://dx.doi.org/10.2174/157016309787581093 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neonatal Fever in the Term Infant: Evaluation and Management Strategies
Current Pediatric Reviews Nanofiber Scaffolds for Treatment of Spinal Cord Injury
Current Medicinal Chemistry Lantibiotic Production by Pathogenic Microorganisms
Current Protein & Peptide Science Subject Index to Volume 4
Current Drug Targets - Infectious Disorders New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design The Indian Pediatric HIV Epidemic: A Systematic Review
Current HIV Research Crosstalk Between Covid-19 and Associated Neurological Disorders: A Review
Current Neuropharmacology Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry Anti-Inflammatory Treatments for Chronic Diseases: A Review
Inflammation & Allergy - Drug Targets (Discontinued) Recent Advances and Challenges in Steroid Metabolomics for Biomarker Discovery
Current Medicinal Chemistry Poly (Lactic-co-Glycolic Acid) & Tocopheryl Polyethylene Glycol Succinate Nanoparticles for the Treatment of Different Brain Cancers
Anti-Cancer Agents in Medicinal Chemistry Aptamers: Molecular Tools for Medical Diagnosis
Current Topics in Medicinal Chemistry Gene Therapy to Improve Pancreatic Islet Transplantation for Type 1 Diabetes Mellitus
Current Diabetes Reviews Psychosocial Stress, Emotions and Cytokine-Related Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Morphofunctional Aspects of the Blood-Brain Barrier
Current Drug Metabolism Editorial (Hot Topic: What can be Done to Improve Confidence and Trust in the Safety of the System for Pharmaceutical Products?)
Current Drug Safety The Nun Study: Risk Factors for Pathology and Clinical-Pathologic Correlations
Current Alzheimer Research The Premature Lottery in the Canadian Grey Zones
Current Pediatric Reviews Recent Advances in Liposomal Drug Delivery: A Review
Pharmaceutical Nanotechnology Nerve Injury Associated with Regional Anesthesia
Current Topics in Medicinal Chemistry